LT3204359T - Tetrahidroizochinolino dariniai - Google Patents

Tetrahidroizochinolino dariniai

Info

Publication number
LT3204359T
LT3204359T LTEP15775688.3T LT15775688T LT3204359T LT 3204359 T LT3204359 T LT 3204359T LT 15775688 T LT15775688 T LT 15775688T LT 3204359 T LT3204359 T LT 3204359T
Authority
LT
Lithuania
Prior art keywords
tetrahydroisoquinoline derivatives
tetrahydroisoquinoline
derivatives
Prior art date
Application number
LTEP15775688.3T
Other languages
English (en)
Inventor
Anne Valade
Eric JNOFF
Ali Ates
Pierre BURSSENS
David SKOLC
Zara Sands
Benoit Mathieu
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of LT3204359T publication Critical patent/LT3204359T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
LTEP15775688.3T 2014-10-08 2015-10-06 Tetrahidroizochinolino dariniai LT3204359T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14188174 2014-10-08
PCT/EP2015/073053 WO2016055479A1 (en) 2014-10-08 2015-10-06 Tetrahydroisoquinoline derivatives

Publications (1)

Publication Number Publication Date
LT3204359T true LT3204359T (lt) 2020-10-12

Family

ID=51790569

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP15775688.3T LT3204359T (lt) 2014-10-08 2015-10-06 Tetrahidroizochinolino dariniai

Country Status (17)

Country Link
US (1) US10105359B2 (lt)
EP (1) EP3204359B1 (lt)
JP (1) JP6622299B2 (lt)
CN (1) CN107001278B (lt)
BR (1) BR112017007123B1 (lt)
CA (1) CA2963951C (lt)
CY (1) CY1123417T1 (lt)
DK (1) DK3204359T3 (lt)
EA (1) EA035544B1 (lt)
ES (1) ES2821821T3 (lt)
HR (1) HRP20201469T1 (lt)
HU (1) HUE050664T2 (lt)
LT (1) LT3204359T (lt)
PT (1) PT3204359T (lt)
RS (1) RS60933B1 (lt)
SI (1) SI3204359T1 (lt)
WO (1) WO2016055479A1 (lt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3419971B1 (en) * 2016-02-25 2022-04-20 Asceneuron SA Glycosidase inhibitors
US10370355B2 (en) 2016-04-13 2019-08-06 Ucb Biopharma Sprl Tetrahydroisoquinoline derivatives
CN107698433A (zh) * 2017-09-12 2018-02-16 潍坊滨海石油化工有限公司 苯乙酸的制备方法
CA3083329A1 (en) * 2017-12-01 2019-06-06 UCB Biopharma SRL Imaging agents
TWI725408B (zh) * 2018-04-20 2021-04-21 美商美國禮來大藥廠 多巴胺d1受體正向異位調節劑
MA56445A (fr) 2019-07-01 2022-05-11 UCB Biopharma SRL Dérivé de tétrahydroisoquinoléine substitué utilisé comme modulateur allostérique positif de d1
CA3139571A1 (en) * 2019-07-01 2021-01-07 UCB Biopharma SRL A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
CN111943930B (zh) * 2020-08-25 2022-11-01 南京三元阳普医药科技有限公司 Lasmiditan的合成工艺
PL4200280T3 (pl) * 2020-10-07 2024-05-20 Eli Lilly And Company Pochodne fenylo-3,4-dihydroizochinolin-2(1h)-ylo-etan-1-onu jako dodatnie modulatory allosteryczne receptora dopaminy d1
JP2023551173A (ja) 2020-12-03 2023-12-07 ユーシービー バイオファルマ エスアールエル オクタヒドロイソキノリニル誘導体
CA3203281A1 (en) * 2020-12-18 2022-06-23 UCB Biopharma SRL Prodrugs of 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]ethanone
KR20230121849A (ko) 2020-12-18 2023-08-21 유씨비 바이오파마 에스알엘 D1 포지티브 알로스테릭 모듈레이터로서 치환된 테트라하이드로이소퀴놀린유도체
EP4262756A1 (en) * 2020-12-18 2023-10-25 UCB Biopharma SRL Amorphous solid dispersions
JP2023554033A (ja) 2020-12-18 2023-12-26 ユーシービー バイオファルマ エスアールエル ジヒドロイソキノリニル誘導体
CA3211261A1 (en) 2021-03-08 2022-09-15 Kevin Michael BIGLAN Use of mevidalen and other d1 positive allosteric modulators in the treatment of hallucinations and dementia-related psychosis
US20240165101A1 (en) 2021-03-09 2024-05-23 Eli Lilly And Company Use of mevidalen and other d1 positive allosteric modulators for slowing of parkinson's disease progression
CN114671810B (zh) * 2022-03-21 2024-03-22 济南鸿湾生物技术有限公司 一种咪唑苯脲的制备方法
CN115611768B (zh) * 2022-11-14 2024-03-05 郑州大学 一种3,4-二氯苯腈的合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766131A (en) * 1980-10-17 1988-08-23 Pennwalt Corporation 2-amino (or hydroxy) phenethyl-1,2,3,4-tetrahydroisoquinolines as analgesics
EP1458714A1 (en) * 2001-12-19 2004-09-22 H. Lundbeck A/S 3,4-dihydro-1h-isoquinoloin-2-yl-derivatives
DK1749001T3 (da) * 2004-04-29 2010-06-28 Aventis Pharma Inc 3-piperidinylisochroman-5-ol som dopaminagonister
RU2009136330A (ru) * 2007-03-01 2011-04-10 Янссен Фармацевтика Н.В. (Be) Тетрагидроизохинолиновые соединения в качестве модуляторов гистаминового н3 рецептора

Also Published As

Publication number Publication date
SI3204359T1 (sl) 2020-10-30
EA201790785A1 (ru) 2017-10-31
JP6622299B2 (ja) 2019-12-18
CY1123417T1 (el) 2021-12-31
PT3204359T (pt) 2020-09-24
HRP20201469T1 (hr) 2020-12-11
BR112017007123B1 (pt) 2023-01-31
CA2963951A1 (en) 2016-04-14
WO2016055479A1 (en) 2016-04-14
ES2821821T3 (es) 2021-04-27
HUE050664T2 (hu) 2020-12-28
EP3204359A1 (en) 2017-08-16
EP3204359B1 (en) 2020-07-01
JP2017530185A (ja) 2017-10-12
DK3204359T3 (da) 2020-09-14
EA035544B1 (ru) 2020-07-03
RS60933B1 (sr) 2020-11-30
CA2963951C (en) 2023-02-28
CN107001278A (zh) 2017-08-01
BR112017007123A2 (pt) 2017-12-19
CN107001278B (zh) 2020-11-24
US10105359B2 (en) 2018-10-23
US20170304292A1 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
LT3204359T (lt) Tetrahidroizochinolino dariniai
IL253381B (en) History of h9–pyrrolo–dipyridine
HK1245258A1 (zh) 新的二氟酮酰胺衍生物
SG11201609205WA (en) Heterocyclyl-butanamide derivatives
HUE050450T2 (hu) Fluoralkil-fluorén-származékok
IL248773A0 (en) History of naphthyridinedione
IL248629A0 (en) Substances containing diheteroaryl conjugated to cycloalkyl and their uses
PL3164393T3 (pl) Pochodne flawaglin
PT3097076T (pt) Novos derivados cyp-eicosanoides
IL251005B (en) Pyrido-oxazinone derivatives
PL3119744T3 (pl) Pochodne 2-cyjano-3-cyklopropylo-3-hydroksy-N-arylo-tioakryloamidu
IL261055B (en) Tetrahydroisoquinoline derivatives
GB201707862D0 (en) Tracers
GB2530305B (en) Tracers
GB201418365D0 (en) Tracers
GB201409664D0 (en) Tracers
GB201407585D0 (en) SMA-Inter Act